Zivo Bioscience | 10-Q: FY2025 Q3 Revenue: USD 65.63 K

Revenue: As of FY2025 Q3, the actual value is USD 65.63 K.

EPS: As of FY2025 Q3, the actual value is USD -0.27.

EBIT: As of FY2025 Q3, the actual value is USD -1.005 M, beating the estimate of USD -1.725 M.

Financial Metrics by Segment

Revenue

• Total Revenue: $65,625 for the three months ended September 30, 2025, compared to $31,500 for the same period in 2024. For the nine months ended September 30, 2025, total revenue was $119,025, compared to $67,220 for the same period in 2024.

Costs of Goods Sold

• Total Cost of Goods Sold: $44,337 for the three months ended September 30, 2025, compared to $22,050 for the same period in 2024. For the nine months ended September 30, 2025, total cost of goods sold was $79,816, compared to $45,268 for the same period in 2024.

Gross Margin

• Gross Margin: $21,288 for the three months ended September 30, 2025, compared to $9,450 for the same period in 2024. For the nine months ended September 30, 2025, gross margin was $39,209, compared to $21,952 for the same period in 2024.

Research and Development Expenses

• Research and Development Expenses: $203,444 for the three months ended September 30, 2025, compared to $326,361 for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $3,452,336, compared to $2,891,452 for the same period in 2024.

General and Administrative Expenses

• General and Administrative Expenses: $836,187 for the three months ended September 30, 2025, compared to $1,943,126 for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $3,446,876, compared to $8,895,978 for the same period in 2024.

Net Loss

• Net Loss: $1,033,056 for the three months ended September 30, 2025, compared to $2,268,597 for the same period in 2024. For the nine months ended September 30, 2025, net loss was $6,884,474, compared to $11,783,451 for the same period in 2024.

Cash Flow

• Cash Flow from Operating Activities: - $2,173,204 for the nine months ended September 30, 2025, compared to - $3,407,788 for the same period in 2024.
• Cash Flow from Financing Activities: $687,984 for the nine months ended September 30, 2025, compared to $3,292,811 for the same period in 2024.

Future Outlook and Strategy

Core Business Focus

• Revenue Growth: The company aims to increase revenue through higher product volumes and expanding sales of its dried algal biomass product as a human food or food ingredient.
• Cost Management: The company plans to manage costs by reducing research and development expenses and general and administrative expenses, as evidenced by the significant decrease in these expenses in 2025 compared to 2024.

Non-Core Business

• Convertible Loan Agreement: The company entered into a Convertible Loan Agreement in July 2025, allowing for up to $2 million of borrowings from investors, with an initial loan of $250,000 at an interest rate of 10%.
• Participation Agreements: The company has entered into Exchange Agreements with participants to buy out their revenue share rights in exchange for common stock, reducing future cash obligations.

Priority

• Funding Requirements: The company estimates it will require approximately $6.0 million in cash over the next 12 months to fund basic operations, excluding research and development initiatives. The company plans to secure additional funding through public or private equity or debt financings, collaborations, or partnerships.